Kidney Cancer

>

Latest News

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.
Belzutifan Significantly Improves PFS Vs Everolimus in Clear Cell RCC

September 4th 2024

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.

Patients receiving immune checkpoint inhibitors for renal cell carcinoma had improved symptom burden when enrolled in a remote exercise program.
Exercise Oncology May Improve HRQOL in Metastatic RCC

July 30th 2024

Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC

July 12th 2024

Efficacy Highlighted in Fianlimab/Cemiplimab in Pretreated Advanced ccRCC
Efficacy Highlighted in Fianlimab/Cemiplimab in Pretreated Advanced ccRCC

July 12th 2024

Manageable AEs Noted in Belzutifan for Advanced RCC
Manageable AEs Noted in Belzutifan for Advanced RCC

July 12th 2024

Latest CME Events & Activities

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

<1
...
2627282930